William Blair Weighs in on Upstream Bio Q4 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Investment analysts at William Blair issued their Q4 2024 EPS estimates for Upstream Bio in a research note issued to investors on Tuesday, November 5th. William Blair analyst M. Phipps expects that the company will post earnings per share of ($0.42) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($12.31) per share. William Blair also issued estimates for Upstream Bio’s FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($2.26) EPS.

Several other brokerages also recently weighed in on UPB. Piper Sandler initiated coverage on shares of Upstream Bio in a research report on Tuesday. They set an “overweight” rating and a $75.00 price target for the company. JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio in a research report on Tuesday. They set an “overweight” rating and a $38.00 price target for the company. Finally, TD Cowen began coverage on shares of Upstream Bio in a research report on Tuesday. They set a “buy” rating for the company.

Upstream Bio Trading Down 3.1 %

UPB stock opened at $26.18 on Thursday. Upstream Bio has a 52-week low of $20.74 and a 52-week high of $29.46.

Insider Activity

In other Upstream Bio news, Director Erez Chimovits acquired 825,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was purchased at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the transaction, the director now directly owns 4,554,873 shares in the company, valued at approximately $77,432,841. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Upstream Bio news, Director Erez Chimovits acquired 825,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was purchased at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the transaction, the director now directly owns 4,554,873 shares in the company, valued at approximately $77,432,841. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were acquired at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the transaction, the insider now owns 1,175,000 shares in the company, valued at approximately $19,975,000. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.